DA-1241

Experimental drug for type 2 diabetes

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[[2-(4-cyclopropylphenyl)ethyl]amino]-2-methylphenyl]methyl]butanoic acid | image = DA-1241.svg | image2 = DA-1241.svg | width = 200 }}

DA-1241 is an investigational drug being developed for the treatment of type 2 diabetes mellitus. It is a small molecule that acts as an agonist of the G protein-coupled receptor GPR119, which is involved in the regulation of glucose homeostasis.

Mechanism of Action

DA-1241 functions by activating the GPR119 receptor, which is predominantly expressed in the pancreas and gastrointestinal tract. Activation of GPR119 leads to the stimulation of insulin secretion from pancreatic beta cells and the release of incretin hormones from the gut, such as glucagon-like peptide-1 (GLP-1). These actions contribute to improved glucose control in individuals with type 2 diabetes.

Pharmacokinetics

The pharmacokinetic profile of DA-1241 has been studied in preclinical models. It is characterized by rapid absorption and a moderate half-life, which supports its potential use as an oral medication. The drug is metabolized primarily in the liver and excreted via the kidneys.

Clinical Development

DA-1241 is currently undergoing clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. Early-phase studies have shown promising results in terms of glucose-lowering effects and tolerability. Further studies are needed to confirm these findings and to determine the optimal dosing regimen.

Potential Benefits

The development of DA-1241 offers potential benefits for patients with type 2 diabetes, particularly those who may not respond adequately to existing therapies. By targeting GPR119, DA-1241 provides a novel mechanism of action that could complement other antidiabetic agents, such as metformin and sulfonylureas.

Challenges and Considerations

While DA-1241 shows promise, there are challenges associated with its development. These include the need for extensive clinical testing to establish long-term safety and efficacy, as well as potential regulatory hurdles. Additionally, the cost of development and eventual pricing of the drug could impact its accessibility to patients.

Related Pages

• Type 2 diabetes mellitus
• G protein-coupled receptor
• Insulin
• Glucagon-like peptide-1